<DOC>
	<DOCNO>NCT01587144</DOCNO>
	<brief_summary>The purpose study determine effectiveness investigational drug call lucanthone , combine temozolomide ( TMZ ) radiation treatment Glioblastoma Multiforme ( GBM ) .</brief_summary>
	<brief_title>Safety Efficacy Study Lucanthone When Used Combination With Temozolomide ( TMZ ) Radiation Treat Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>This international , multicenter , randomize , double blind placebo control phase II study evaluate safety efficacy lucanthone administer adjunct patient receive primary treatment GBM temozolomide radiation . Eligible patient randomize lucanthone placebo arm ratio 1:1 . The treatment period two phase ; initial six week concomitant therapy temozolomide radiation , follow maintenance phase six cycle temozolomide give Days 1 5 28- day cycle ( +/- 3 day ) . Lucanthone / placebo give add concomitant maintenance phase .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lucanthone</mesh_term>
	<criteria>Main 1 . 18 70 year age India , 18 year US 2 . Histologically proven GBM May may undergo surgery Is schedule receive treatment temozolomide radiation . 3 . Karnofsky score ≥ 70 % . Main 1 . Diagnosis recurrent brain tumor . 2 . Received temozolomide previously . 3 . Absolute neutrophil count ≤ 1.5 X 109/L . 4 . Screening platelet count &lt; 100 K/uL . 5 . Screening bilirubin &gt; 1.6 mg/dL . 6 . Screening creatinine &gt; 2.25 mg/dL men 1.8 mg/dL woman . 7 . Screening ALT AST &gt; 2.5 time upper limit laboratory reference range . 8 . Unstable medical condition significant comorbid pathophysiology ( e.g . active infection , poorly control diabetes , unstable angina , severe heart failure ) would interfere his/her participation study . 9 . Enrolled , plan enroll , concurrent treatment protocol another investigational product . 10 . Receiving , plan receive , anticancer therapy temozolomide study . 11 . Received prior chemotherapy radiation therapy within four week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>GBM</keyword>
</DOC>